Newer agents such as IL-23 antagonists (e.g., Skyrizi) and JAK inhibitors have been integrated into the 2025 treatment algorithms.
Intestinal ultrasound (échographie intestinale) is now formally recognized as a reliable, non-invasive tool for routine follow-up and monitoring treatment efficacy. Download Nouvelles recommandations dans les MICI pdf
The latest clinical guidelines for (Maladies Inflammatoires Chroniques de l'Intestin), specifically Crohn's Disease (MC) and Ulcerative Colitis (RCH), focus on early intervention, "treat-to-target" strategies, and the integration of new-generation biological therapies like Skyrizi . Key Updates in MICI Management (2024–2026) Newer agents such as IL-23 antagonists (e
Provides patient-centered updates and the AFAMAG 2025 Management Report (PDF) which discusses emerging "combiotherapy" strategies. Specific consensus documents, such as the ECCO Consensus
Guidelines now shift away from the traditional "step-up" approach. Clinicians are encouraged to initiate advanced therapies (biologics or small molecules) earlier for moderate-to-severe cases to prevent irreversible tissue damage.
Specific consensus documents, such as the ECCO Consensus on Dietary Management, highlight the role of diet in inducing and maintaining remission. Where to Download Official PDF Guidelines